J Med Drug Rev 2012;2;31-39 (Review-Artikel in deutscher Sprache) Multiple sclerosis (MS) often starts in early adulthood und thereafter typically takes a course over several decades. However, clinical studies in MS with usual treatment periods of one to three years cover this long-term course only inadequately. In contrast to this, […]

J Med Drug Rev 2012;2;19-30 (Review-Artikel in deutscher Sprache) Molecularly targeted therapies have widened considerably the spectrum of medically treatment options for the advanced renal cell carcinoma (RCC). Additionally to cytokines, several anti-VEGF (vascular endothelial growth factor) therapies and inhibitors of the mTOR (mammalian target of rapamycin) pathway are available. […]

J Med Drug Rev 2012;2;13-18 (Review-Artikel in deutscher Sprache) Major orthopedic surgical procedures such as knee or hip replacement surgeries are associated with a high risk of deep venous thrombosis (DVT) and related complications. Therefore, these patients need thromboprophylactic treatments being performed in most cases with subcutaneously injected low molecular […]

J Med Drug Rev 2012;2;5-12 (Review in English and German language) Treatment of hepatic encephalopathy (HE) is still a challenge as the efficacy of the former gold-standard lactulose has been questioned. In addition to disturbed ammonia processing due to chronic liver dysfunction, further pathophysiological mechanisms such as inflammation and infection […]

J Med Drug Rev 2011;1;45-52 (Review-Artikel in deutscher Sprache) Belatacept is a new treatment option for the prevention of acute organ rejection in patients after kidney transplantation. Its mode of action totally differs from all known therapies. Belatacept is a selective blocker of T-cell activation, which plays a big role […]

J Med Drug Rev 2011;1;29-36 (Review-Artikel in deutscher Sprache) Fingolimod is a new significant option for oral treatment of multiple sclerosis. Its mode of action totally differs from all known standard therapies. Fingolimod binds to the sphingosine-1-phosphate-receptor on lymphocytes, blocks lymphocyte migration from lymph nodes and thus reduces the infiltration […]